Separate ingredient identity from brand approval
FDA distinguishes semaglutide sodium and acetate from the ingredient in approved drugs and reports no known lawful basis for using those salts in compounding. A matching milligram quantity cannot resolve that identity difference.
Documentation to request
Obtain the exact ingredient form, finished-product label and supplying facility identity. Record the current legal basis for the proposed transaction rather than a historical shortage exemption.
Regulatory context: FDA: unapproved GLP-1 drugs and ingredient restrictions. Source reviewed . This source does not verify the identity, testing or availability of our catalog references.
Related guidance: Weight-loss clinic sourcing requirements. These references support a review, not a treatment recommendation or supply authorization.